EC
MRNS

EcoR1 Capital’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

EcoR1 Capital’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-905,568
Closed -$21.3M – 47
2017
Q3 		$21.3M Buy
+905,568
New +$10.2M 2.83% 9

Other funds holding MRNS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
AC
Ascend Capital Orinda, California $1.99B AUM 10.37% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

EcoR1 Capital's MRNS Position: Q4 2017 in Review

EcoR1 Capital sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2017, closing a stake of 905,568 shares — an estimated $21.3M sold.

EcoR1 Capital first reported a position in MRNS in Q3 2017 and held it in 1 quarter. The position peaked at $21.3M in Q3 2017. 65 funds tracked by Wall St. Rank hold MRNS as of Q4 2017.

  • EcoR1 Capital reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2017 after selling out during the quarter.
  • EcoR1 Capital sold 905,568 Marinus Pharmaceuticals, Inc shares in Q4 2017, an estimated $21.3M.
  • EcoR1 Capital first reported a position in Marinus Pharmaceuticals, Inc in Q3 2017 and held it in 1 quarter.
  • EcoR1 Capital's Marinus Pharmaceuticals, Inc position peaked at $21.3M in Q3 2017.
  • 65 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2017.

Based on EcoR1 Capital's 13F filing for Q4 2017, filed 14 Feb 2018.